Howard Kallender

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 5

Top Topics

Pluripotent Stem Cells

Physical Activity

Atopic Dermatitis

Top Venues

Dermatology and therapy

Drug design, development and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Eric L Simpson, Leon Kircik, Andrew Blauvelt, Howard Kallender, Daniel Sturm, Mingyue Wang, Lawrence F Eichenfield
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies. Dermatology and therapy 14 (8) (2024)
Eric L Simpson, Leon Kircik, Andrew Blauvelt, Howard Kallender, Daniel Sturm, Mingyue Wang, Lawrence F Eichenfield
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies. Dermatology and therapy 14 (8) (2024)
Eric L Simpson, Leon Kircik, Andrew Blauvelt, Howard Kallender, Daniel Sturm, Mingyue Wang, Lawrence F Eichenfield
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies. Dermatology and therapy (2024)
Eric L Simpson, Leon Kircik, Andrew Blauvelt, Howard Kallender, Daniel Sturm, Mingyue Wang, Lawrence F Eichenfield
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies. Dermatology and therapy 14 (8) (2024)
Jason D Lickliter, Hui K Gan, Mark Voskoboynik, Surein Arulananda, Bo Gao, Adnan Nagrial, Peter Grimison, Michelle Harrison, Jianjun Zou, Lianshan Zhang, Stacey Luo, Michael Lahn, Howard Kallender, Andrea Mannucci, Catello Somma, Katherine Woods, Andreas Behren, Pablo Fernandez-Penas, Michael Millward, Tarek Meniawy
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug design, development and therapy 14 (2020)